COMPANY 

INSIGHT

 CaP

CaP produces synthetic calcium phosphate raw materials that are intended to be incorporated into medical devices by our customers. The mineral phase of bone is a calcium phosphate, hydroxyapatite, and the major use of synthetic calcium phosphates is in devices intended for use in bone grafting procedures.


CaP was founded in 2006 in order to satisfy a need for an independent source of high quality calcium phosphates. CaP is independent in the sense that CaP does not produce finished devices, so it does not compete with its customers. CaP’s in-depth knowledge of calcium phosphates enables it to produce customized products suited to specific customer applications. This enables the customer to obtain exactly what is needed without having to be expert in calcium phosphate technology.

Background:

Calcium phosphate grafting materials are typically thought of as generic, commodity materials. However, their chemistry and physical properties are highly complex and have significant implications for their biological functioning.

All calcium phosphates are calcium salts of phosphoric acid meaning they are made by reacting an acid (phosphoric acid) with a base (calcium compound). The most common calcium phosphate is a mineral; apatite; which is an ionic crystalline material that is found in natural geological deposits. Apatites are the only water stable calcium phosphate salts. Since bone is formed in a water based environment it is no surprise that the mineral portion of bone is an apatite mineral (hydroxyapatite, HA). When apatites crystalize they incorporate not only calcium, but also a wide variety of other metals in various combinations and ratios. Body fluids are rich in trace minerals, so bone apatite is not a pure calcium phosphate either, it incorporates traces of other metals including magnesium, zinc, strontium, silicon, etc., as well as counter ions to the “free” metals other than hydroxide; fluorine and carbonate being the most common.

The trace ion profile 

The trace ion profile of hydroxyapatite can have significant effects on its physical and biological properties. One of the most obvious is the substitution of fluorine for hydroxide. Teeth are made of hydroxyapatite and fluoride treatment reduces the solubility of the apatite significantly enough to practically eliminate cavity formation.


Other ionic substitutions such as carbonate for phosphate or hydroxide, or other metals for calcium, are generally regarded as being more favorable to bone growth. The reasons are not fully understood but one theory is that since bone apatite naturally incorporates these ions from body fluids, bone forming cells evolved with these substituted apatites so that similar ion profiles in synthetic materials will make them more acceptable to the body. Another reason might be that foreign ions disrupt the apatite crystal structure so that it dissolves (remodels) more readily. It is also possible that foreign ions help the apatite to better bind proteins that are involved in the bone formation process.


Synthetic apatite is usually sintered, meaning it is heated to a high temperature (around 11000C) so that the individual apatite crystals fuse, grow larger, and interlock, providing mechanical strength. Without sintering, apatite is just a hard to handle micron sized powder. Sintering allows apatite to be made into useful forms such as simulated, ground cancellous bone, for example. However, natural bone is obviously not sintered. Its strength comes from a networked collagen substrate that carries the micron sized apatite crystals. Thus, the micro structure of synthetic apatite is much different from bone; synthetic apatite is a fused, relatively low porosity structure while bone is a highly porous composite of collagen and micro apatite crystals. So specifying synthetic hydroxyapatite (HA) as a bone grafting material because bone contains hydroxyapatite is not the best solution even though it initially appears logical.

Actually, synthetic calcium phosphates other than HA are better bone grafting materials. For example, tricalcium phosphate (TCP) has now become the most widely used synthetic calcium phosphate graft material. TCP is very similar to HA except that TCP is not stable in water. Thus, after implantation, the surface of a TCP graft soon transforms to water stable HA. The newly formed apatite surface is biological apatite, such as is naturally found in bone, and results in a more biocompatible graft.


This is just one example of a calcium phosphate application. The possibilities for customization are virtually unlimited; such as modifying micro-porosity and/or surface properties, incorporating different trace element profiles, changing the sintering conditions, or even producing self-setting calcium phosphate cements based on the metastable materials alpha TCP or tetracalcium phosphate. These variations can, for example, affect the graft remodeling rate, the initial healing rate, the resistance of the graft to dissolution in the presence of inflammation, the suitability of the graft as a carrier for added stem cells, peptides or proteins, the suitability of the graft for incorporation into composite materials with polymers or collagen, and the graft surgical handling properties.

Summary:

CaP Biomaterials has the knowledge and experience to work with customers’ technical staff to develop custom calcium phosphates that are optimized for specific application(s). We can help with background advice, sample fabrication, validation samples and scale up to production quantities.

Go to article: Home | The dawn of digital healthGo to article: In this issueGo to article: Telemed Company InsightGo to article: TelemedGo to article: ContentsGo to article: Formacoat Company InsightGo to article: FormacoatGo to article: Nelson Labs Company InsightGo to article: Nelson LabsGo to article: Nanokicking: a new method to grow bone from stem cellsGo to article: Electronic Sensor TechnologyGo to article: IMT Company InsightGo to article: IMTGo to article: Silicon Valley Bank: Funding med tech innovation from the ground upGo to article: Röchling Medical NeuhausGo to article: Medica LLC Company InsightGo to article: Medica LLCGo to article: A breakthrough in wireless charging for implantsGo to article: Accurate Biometrics Company InsightGo to article: Accurate BiometricsGo to article: Machine Solutions Company InsightGo to article: Machine SolutionsGo to article: Molecular imaging: nipping drug failure in the bud Go to article: Cap Biomaterials Company Insight Go to article: Cap BiomaterialsGo to article: Tricor Systems Company InsightGo to article: Tricor SystemsGo to article: Tech watch: machine learning in healthcareGo to article: Bright PlasticsGo to article: goMed2MedGo to article: Optimising the care pathway: A vision of connected healthcare deliveryGo to article: Velixx Company InsightGo to article: VelixxGo to article: Ginolis Company InsightGo to article: GinolisGo to article: Disposable diagnostics: fighting antimicrobial resistance in the field Go to article: Sab Broeckskes Gmbh & Co. KgGo to article: Inside Costa Rica’s super-sized medical device sectorGo to article: ARPAGo to article: 3D printed medical devices: a tough trial for regulation?Go to article: Walter+Bai AG Company InsightGo to article: Walter+Bai AGGo to article: Breaking point: should we be reusing more medical devices?Go to article: Protomatic Company InsightGo to article: Protomatic MedicalGo to article: EventsGo to article: Next issue